Welcome to ViraTherapeutics

Viruses designed for cancer therapy

 

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients in 2018 at the earliest.

 

Press release - May 30, 2017

 

ViraTherapeutics appoints Heinz Schwer as CEO

Press release BI ViraTherapeutics - May 30, 2017
20170530_PR-ViraT-CEO_ENG_final.pdf
PDF-Dokument [73.3 KB]
Pressemitteilung BI ViraTherapeutics - 30. Mai 2017
20170530_PR-ViraT-CEO_GER_final.pdf
PDF-Dokument [75.3 KB]

 

“I am very happy that we could attract Dr. Schwer to join ViraTherapeutics as CEO. Fueled by our strong R&D partnership with Boehringer Ingelheim, ViraTherapeutics is transitioning from a pre- clinical stage company to a clinical stage company. We are convinced that Dr. Schwer, with his experience and track record, is the right person to lead ViraTherapeutics into the future,” said Dr. Klaus Schollmeier, chairman of the supervisory board of ViraTherapeutics.

 

Druckversion Druckversion | Sitemap
© ViraTherapeutics GmbH